Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

Published:2019-07 Issue:1 Volume:81 Page:173-178
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Egeberg Alexander,Bryld Lars Erik,Skov Lone

Funder

Pfizer

Eli Lilly and Company

National Psoriasis Foundation

Kgl Hofbundtmager Aage Bang Foundation

AbbVie

Novartis

Sanofi

Janssen Cilag

Leo Pharma

Publisher

Elsevier BV

Subject

Dermatology

Reference10 articles.

1. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis;Gordon;N Engl J Med,2016

2. Secukinumab in plaque psoriasis–results of two phase 3 trials;Langley;N Engl J Med,2014

3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

4. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry;Egeberg;J Eur Acad Dermatol Venereol,2017

5. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis;Egeberg;Br J Dermatol,2018

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study;Journal of Cutaneous Medicine and Surgery;2024-09-03

2. A Comprehensive Review of the Factors Affecting the Redefinition of Therapeutic Use in Metropolitan Cities during the Emerging and Re-emerging Pandemics;Romanian Journal of Military Medicine;2024-09-01

3. Investigating EGFR, BRAF, and RAS Mutations in Oral and Cutaneous Squamous Cell Neoplasms: A Preliminary Report on Romanian Patients;Romanian Journal of Military Medicine;2024-09-01

4. Drug survival of interleukin 17 inhibitors after switch from interleukin 23 inhibitors in psoriasis: An observational cohort study;Journal of the American Academy of Dermatology;2024-09

5. Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study;Journal of the American Academy of Dermatology;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3